Suboptimal Surveillance for and Knowledge of Hepatocellular Carcinoma Among Primary Care Providers by McGowan, Christopher E. et al.
Suboptimal Knowledge of and Surveillance for Hepatocellular 
Carcinoma by Primary Care Providers
Christopher E. McGowan, MD, MSCR1, Teresa P. Edwards, BS, MA2, Mai-Uyen T. Luong, 
BA1, and Paul H. Hayashi, MD, MPH1
1UNC Liver Center Division of Gastroenterology and Hepatology Burnett-Womack Bldg., Room 
8011 Chapel Hill, NC 27599-7584
2H. W. Odum Institute for Research in Social Science University of North Carolina - Chapel Hill 
CB# 3355, 231D Davis Library Chapel Hill, NC 27599-3355
Abstract
Background & Aims—A large proportion of patients with cirrhosis are seen only by their 
primary care provider (PCP). Surveillance for hepatocellular carcinoma (HCC) therefore depends 
on PCPs in these cases. We aimed to assess PCP knowledge and practice of HCC surveillance.
Methods—We contacted a random sample of 1000 North Carolina PCPs by mail. All received an 
introductory letter, followed by a 12-item questionnaire addressing HCC surveillance knowledge 
and practice.
Results—Three hundred ninety-one PCPs (39%) completed the survey; 89% saw patients with 
cirrhosis in their practice, but only 45% screened for HCC. Among PCPs who screened, the most 
common methods were ultrasound analysis and measurement of [α] fetoprotein (66%). Reasons 
for surveillance included supported by evidence (72%), recommended by medical societies (42%), 
and malpractice liability for not surveilling (26%). Of PCPs who did not screen, 84% referred to 
gastroenterologists for surveillance decisions, 24% were unaware of recommendations, 8% were 
uncertain of the benefits, and 8% were concerned over cost. Hepatic resection and liver 
transplantation were identified as effective therapies by 67% and 56% of PCPs, but all other 
effective therapies were identified by less than half (transarterial chemoembolization by 42%, 
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radiofrequency ablation by 35%, sorafenib by 26%). Ability to identify at least 1 effective therapy 
was independently associated with surveillance (odds ratio, 2.1; 95% confidence interval, 1.1−4.0)
Conclusions—Most PCPs see patients with cirrhosis, but only a minority screen for HCC. PCP 
knowledge of effective HCC therapy options is suboptimal. Efforts to enlist PCPs in HCC 
surveillance may be best served by increasing their knowledge of effective therapies.
Keywords
therapy; screening; hepatitis C; hepatitis B; cirrhosis
INTRODUCTION
Hepatocellular carcinoma surveillance is recommended by all three major hepatology 
societies.(1-3) Nevertheless, surveillance rates remain well below 50% and in some 
populations as low as 12%.(4-7) Among the many steps needed for surveillance to be 
accomplished, physician education and incorporation of surveillance into their practice are 
critical. As expected, hepatologists and gastroenterologists tend to believe in surveillance 
and are more likely to routinely order it for their cirrhotic patients (5, 7) but only 20-50% of 
such patients are seen by such subspecialists. (7, 8) Primary care providers (PCPs) see most 
of the remainder.
Therefore, if surveillance is to have any chance of reaching more than 50% of cirrhosis 
patients, enlistment of PCPs will be necessary. Only 3 studies have investigated the practice 
and knowledge of HCC surveillance amongst PCPs and these 3 focused primarily on PCPs 
who see a high number of Asian patients or on surveillance for viral hepatitis rather than 
HCC surveillance. (9-11) Therefore we sampled PCPs from the entire North Carolina 
Medical Board database and limited our questionnaire to HCC surveillance only.
METHODS
Institutional Review of Research
Our research project and protocol were reviewed and approved by the University of North 
Carolina Institutional Review Board prior to initiating this study.
Subjects
We used the North Carolina Medical Board database to identify practicing primary care 
providers (physicians and doctors of osteopathy) in North Carolina. A random sample of 
1000 PCPs was identified. This sample represented 14% of North Carolina PCP's (12),(13)
Survey
Survey methodology is based on the tailored design method.(14) All subjects received an 
introductory letter, followed by the questionnaire in a separate mailing. The questionnaire 
consisted of 8-items addressing knowledge and use of HCC surveillance guidelines as well 
as identification of HCC therapies. Basic demographics and practice information requested 
was limited to gender, years in practice, major affiliations (e.g. academic facility, Veterans 
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Affairs, private practice) and their ability to see Medicaid covered patients. We purposely 
did not request more specific information that would lengthen the questionnaire, 
compromise anonymity and potentially lower the response rate. Therefore we did not collect 
information on practice location, type of service area (rural versus urban), training, or 
specific type of practice (i.e. group versus solo, family practice versus internal medicine) or 
personal perceptions of surveillance efficacy. Such limiting of variables did not allow us to 
construct a conceptual behavioral model for the decision to recommend surveillance. 
Instead, we focused on self-reported rate of surveillance, and the modality and interval 
recommended. We also asked about knowledge of HCC therapies because they have 
changed substantially in the last decade and remain a primary justification for surveillance. 
No pre-testing or validation of this brief survey were done. A $10 cash incentive was 
included to reduce non-response bias and was given regardless of whether the PCP 
completed the questionnaire or not. A reminder/gratitude postcard was mailed to all 
subjects, followed by the mailing of a second questionnaire for non-responders. Addressed 
return envelope with pre-paid postage was included.
To ensure anonymity, all questionnaires were given an alphanumeric code. The master key 
linking code to subject name was used only at the mail out and receipt portion of the study 
to determine who should receive a second chance mailing. Data collection (receipt of 
questionnaires) was closed 90 days after the last mailing was completed. Thereafter the 
master key was destroyed and no further questionnaires were collected or mailed out.
Analysis
Demographic, practice information, and survey responses were analyzed using basic 
descriptive statistics (e.g. means, medians, proportions, standard deviations). We used 
Pearson Chi-Square and T-test where appropriate to compare PCPs who screened and those 




Of the 1000 PCPs to whom we mailed letters and questionnaires, 391 (39%) completed the 
questionnaire and mailed it back to us. Two PCPs answered questions in an incongruent or 
unclear manner and had to be discarded (one PCP indicated not seeing cirrhotic patients yet 
did surveillance; another did not answer whether they saw cirrhotic patients, but indicated 
they do not screen.) Characteristics of the remaining 389 PCPs is shown in Table 1. The vast 
majority was in private practice and saw Medicaid patients. Nearly 90% saw cirrhotic 
patients in their practices.
Hepatocellular carcinoma (HCC) surveillance
Of the 345 PCPs that saw cirrhotic patients, only 45% recommended HCC surveillance. 
There were no significant differences between those PCPs who do recommend surveillance 
(n = 156) from those who don't (n = 189) in terms of gender, years in practice, practice 
affiliation and whether they see Medicaid patients. The most common means of surveillance 
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used was liver ultrasound and alpha-fetoprotein measurement. (Figure 1) The most common 
interval for surveillance was 12 months. (Figure 2) Nearly three quarters of those who 
provide surveillance do so because they felt evidence supported it (Table 2). When asked to 
identify barriers to surveillance, 54% identified poor patient adherence and 53% identified 
patient financial constraints, 49% lack of insurance and 32 % insurance constraints on 
coverage. Only 5% identified lack of available surveillance services (e.g. radiology) as a 
barrier.
Among those who do not recommend surveillance, the vast majority (84%) defer to 
subspecialists to decide or carry out surveillance (Table 3). However, 46 (24%) were 
unaware of any surveillance recommendations, while only 15 (8%) felt the benefit of 
surveillance was uncertain. Only 4% identified cost as a reason for not recommending 
surveillance.
Knowledge of HCC therapies and association with surveillance
Of the 345 PCPs who see cirrhosis patients, 230 (67%) identified resection as an effective 
therapy for HCC, but only 192 (56%) identified liver transplant. (Table 4) Other effective 
treatments were identified less frequently. PCPs who were able to identify at least one 
modality as an effective therapy were more likely to screen with an odds ratio of 1.9 (p = 
0.04). On multivariate analysis (controlling for PCP gender, practice setting, years in 
practice and whether they see Medicaid patients), the association between identifying at 
least one effective therapy and recommending surveillance remained significant (OR 2.1, 
95% confidence interval 1.1 − 4.0). None of the other variables were significantly associated 
with recommending surveillance.
DISCUSSION
While formally recommended by hepatology societies for nearly a decade, less than half 
(25-42%) of cirrhotic patients receive HCC surveillance according to several studies.(4-7) 
Such low rates may be because 20-50% of cirrhosis patients are not seen by 
gastroenterologists who tend to recommend surveillance more than PCPs.(7, 8) Even after 
being seen by a gastroenterologist, patients may see their PCP more frequently, especially in 
remote regions where the distance to a subspecialist is greater. If surveillance is to ever have 
a sustainable rate over 50%, enlistment of PCP help will probably be necessary. However, 
data regarding PCP knowledge and beliefs regarding HCC surveillance are limited.
Our study indicates that only 45% of primary care providers who see cirrhosis patients in 
North Carolina recommend surveillance. About 70% of PCPs who screen, do so because 
they feel evidence supports it. Forty-two percent understood that some medical associations 
recommend it. Of the majority that do not screen, 84% deferred to subspecialists to 
recommend or consider surveillance, and 24% were unaware of surveillance 
recommendations. Only resection and transplantation were correctly identified as effective 
therapies by more than half of all respondents (67% and 56% respectively). (Table 4) Only 
35% identified RFA, even though data suggest it rivals resection in efficacy and is 
significantly less morbid. (15-17). Similarly, only a minority of PCPs identified TACE and 
sorafenib despite randomized controlled trials (RCT) showing survival benefit.(18, 19) 
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Those PCP's able to identify at least one effective treatment were twice as likely to 
recommend surveillance.
Of those who do surveillance, US and AFP, in combination, was most commonly used, and 
12 months the most common interval. (Figures 1 & 2). These data may reflect older AASLD 
recommendations of 2005 in which AFP was mentioned as an alternative option, if US is 
suboptimal or unavailable, and the suggested interval was up to 12 months. In 2010, the 
AFP was completely dropped and the interval limited to 6 months.
Two studies reported higher rates of surveillance among PCPs (79-89%), but the PCPs in 
these studies were highly biased toward increased HCC awareness. Both studies targeted 
PCPs from communities with high proportions of Asians who have significantly higher 
prevalences of hepatitis B infection and consequent cirrhosis. Also, PCPs in these studies 
may recommend surveillance more often because supporting evidence is stronger (Level I, 
RCT data) for surveillance in hepatitis B related liver disease (20) than cirrhosis from other 
etiologies (Level II, observational, cohort data) (21). One study surveyed 11 San Francisco 
clinics with a patient population that is 25% Asian.(10) Moreover, 1 in 4 of the PCPs 
themselves were Asian and half had patient panels that were >25% Asian. The other study 
surveyed 3 Northern California counties, but again 1 in 4 of the PCPs were Asians, 43% 
spoke an Asian language and 30% of their catchment was Asian.(9) Such PCP groups will 
have an increased interest in HCC surveillance compared to PCPs from other areas of the 
U.S. The nation as a whole is only 5% Asian.(22) The only other study examining PCPs 
focused primarily on surveillance for hepatitis C and B infections.(11) HCC surveillance 
questions were limited and did not specify the presence or absence of cirrhosis. None of the 
three studies asked about HCC therapies or whether respondents actually see cirrhosis 
patients in their practices.
We focused on HCC surveillance and therapy. We surveyed a random sample of PCPs from 
across the state of North Carolina. Therefore, our data are more representative of 
communities with Asian prevalence closer to the national average. Only 2.5% of North 
Carolina are of Asian descent.(13) Unlike prior surveys we also asked whether PCPs 
actually saw cirrhosis patients in their practice. Such determination is critical since PCPs 
may render an opinion on HCC surveillance but never actually see a cirrhotic patient. Some 
may divert cirrhosis patients away from their clinic, or work in clinics where cirrhosis 
patients are rare (e.g. student health clinics).
We also wanted to understand PCP knowledge of HCC therapies because effective therapies 
are arguably the most compelling justification for surveillance.(1, 23) HCC therapies have 
evolved greatly in the last 12 years. Our survey suggests that PCP knowledge of more 
recently established treatments is relatively poor compared to established surgical 
interventions. Filling this knowledge gap regarding RCT data for TACE, RFA and 
sorafenib, could increase surveillance rates by PCPs since the ability to identify at least one 
effective therapy was independently doubled the odds of surveillance. Also, over 80% of 
PCPs who do not screen deferred the decision to subspecialists, and despite some 
controversy in the literature regarding HCC surveillance recommendations, (23-25) only 8% 
McGowan et al. Page 5













did not screen because the “benefit is uncertain”. Therefore, a large number of PCPs may 
recommend surveillance, if guidance and education are provided.
Our study is limited by a response rate (39%) that is lower than prior HCC surveillance 
surveys of PCPs (62-71%).(9, 10) As mentioned, these prior studies targeted Asian 
community PCPs who very likely have a deeper knowledge and interest in HCC. Our 
response rate is more in line with less targeted provider surveys. An analysis of 130 surveys 
of US health care professionals, conducted from 1996 to 2005 yielded a median response 
rate of 51% with an interquartile range of 38-65%.(26) Moreover, the response rate for 
health care professionals declined significantly with the percent of surveys having >60% 
response falling from 63% prior to 2000 to 35% in 2005-2008.(27) PCPs who see pertinence 
in a survey and have increased knowledge of the topic tend to respond more often, hence the 
higher response rates in the studies from California.(9, 10, 28) Such a response bias in our 
study would make our surveillance and knowledge of therapy rates overestimates of the true 
rate amongst PCPs in our state. Moreover, recall bias by those who said they recommend 
surveillance may further overestimate the rate.
Our survey is also limited in scope. The questionnaire was purposely kept brief to limit the 
non-response rate. Many other variables needed for a full behavior model such as PCP 
access to subspecialists and volume of cirrhotic patients seen were not included. Thus, 
therapy knowledge that was associated with surveillance may be merely a surrogate for 
other more pertinent variables not captured in our survey.
Our study provides the only data on HCC surveillance and knowledge of HCC therapy in an 
unselected population of PCPs who see cirrhotic patients in practices not enriched with 
Asians. The data suggest that HCC surveillance rates and knowledge of therapies are low. It 
also suggests an opportunity to increase community surveillance rates by closing the gap in 
knowledge, particularly regarding effective therapy options. Moreover the majority of PCPs 
who do not screen may be amenable to surveillance if educated and guided by 
subspecialists. Enlisting PCP help in initiating surveillance may eliminate unnecessary 
referral for opinion and certainly will help with sustaining surveillance once started. It is 
probably the only practical way to increase and sustain surveillance rates on a broader scale.
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Modality of HCC surveillance used by those primary care providers who screen (n = 156). * 
“Other” category for modality: 2 PCPs indicated they would do what the subspecialist 
recommends, while 4 used AFP, US, CT and MRI in various combinations and alternating 
fashion (e.g. AFP + US every 6 months and CR or MRI every 2 years).
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Interval of HCC surveillance used by those primary care providers who screen (n = 156). ^ 
“Other” category for interval: 2 PCPs gave ranges of 6-12 months, 5 indicated taking cues 
from subspecialists and 8 gave unclear answers for interval (e.g. “depends” and 
“periodically” and “if liver enzymes rise”). AFP = alpha-fetoprotein, US = ultrasound, CT = 
computerized tomography, MRI = magnetic resonance imaging.
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Table 1
Characteristics of primary care providers (n = 389)
Characteristic
Male, n (%) 234 (60.2)
Years in practice (mean, standard deviation) 22 (9.9)
Primary affiliation, n (%)
        Private practice 313 (80.5)
        Academic setting 47 (12.1)
        Veterans Affairs hospital or clinic 13 (3.3)
        Health maintenance organization (HMO) 4 (1.0)
        Other (not specified by respondent) 12 (3.1)
Encounter cirrhotic patients in practice, n (%) 345 (88.7)
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Table 2
Reasons for recommending HCC surveillance among those PCPs that screen, n = 156 (respondents asked to 
choose all that apply)
n %
Evidence supports surveillance for HCC 112 72
Surveillance is recommended by medical societies 65 42
Not surveillance would pose a malpractice liability 41 26
Surveillance for HCC is cost-effective 26 17
Other
* 12 8
Did not give a reason 4 3
*
Other reasons given: Affects treatment options; it is standard with our cirrhosis clinic; It's what I would do; patients request it; r/o liver lesion 
affecting labs etc.; recommended by consultant (gastroenterologist or hepatologist).
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Table 3
Reasons for not recommending HCC surveillance among those PCPS that do not screen, n = 189 (respondents 
asked to choose all that apply)
n %
Refer cirrhotic patients to consulting provider 158 84
Did not know it was recommended 46 24
Benefit of surveillance is uncertain 15 8
Too costly 8 4
Other
* 8 4
Did not give a reason 0 0
*
Other reasons given: Transient population; I screen the hepatitis C cirrhotics/not usually the alcoholic cirrhotics; Not sure of latest 
recommendations; See few cirrhotics + usually terminal or followed by specialists; Only check with hep C; Ultrasound often done as diagnosis of 
cirrhosis evolving; Usually do not live long enough; I intend to but some slip through
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Table 4
Effective HCC therapies identified by PCPs who see cirrhosis patients, n = 345 (respondents asked to choose 
all that apply)
n %
Hepatic resection 230 67
Liver transplantation 192 56
Transarterial chemoembolization 146 42
Radiofrequency ablation 121 35
Sorafenib 91 26
Did not identify any choices as effective therapies 50 15
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